依非韦伦抗逆转录病毒治疗与高剂量利福平对异烟肼及其乙酰化代谢物药代动力学的影响
该研究为RAFA随机对照试验的药代学子研究,纳入150例TB/HIV共感染患者,分析异烟肼和乙酰异烟肼浓度。结果显示,在快乙酰化者中,基于依非韦伦的抗逆转录病毒治疗使异烟肼AUC0-24降低29%(6.73 vs 4.68 mg·h/L),而慢乙酰化者无影响;利福平剂量增加50%未影响异烟肼及其代谢物药代动力学。
要点
- 快乙酰化者接受依非韦伦方案时异烟肼暴露降低29%。
- 慢乙酰化者中依非韦伦对异烟肼暴露无影响。
- 利福平剂量增加50%未改变异烟肼药代动力学。
核心结论
- 基于依非韦伦的抗逆转录病毒治疗影响快乙酰化者的乙酰化代谢途径,导致异烟肼暴露降低。
- 异烟肼和乙酰异烟肼的药代动力学不受利福平剂量增加50%的影响。
研究设计与样本
- 来自西非RAFA三治疗组随机对照试验的药代学子研究。
- 纳入150例TB/HIV共感染患者,其中79例(53%)同时有乙酰异烟肼浓度。
- 在抗结核治疗开始后4至8周的单次访视中采集5个系列血样,采用非线性混合效应模型分析。
主要发现
- 快乙酰化者接受基于依非韦伦的抗逆转录病毒治疗时,预测AUC0-24降低29%(6.73 vs 4.68 mg·h/L)。
- 慢乙酰化者中基于依非韦伦的抗逆转录病毒治疗对异烟肼暴露无影响(AUC0-24=17.5 mg·h/L)。
关键数值与推荐
- 快乙酰化者接受依非韦伦方案时异烟肼AUC0-24为4.68 mg·h/L,未接受时为6.73 mg·h/L。
- 慢乙酰化者接受依非韦伦方案时异烟肼AUC0-24为17.5 mg·h/L。
临床怎么用
- 对接受基于依非韦伦抗逆转录病毒治疗的TB/HIV共感染快乙酰化者,需关注异烟肼暴露降低的潜在影响。
- 利福平剂量增加50%时无需因异烟肼药代动力学改变而调整剂量。
局限性
- 仅79例(53%)患者有乙酰异烟肼浓度数据。
- 药代动力学采样为单次访视,未评估长期变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of isoniazid and acetyl-isoniazid. METHODS: TB/HIV-coinfected patients participating in the three-treatment-arm RAFA randomized controlled trial conducted in West Africa were recruited into the pharmacokinetics sub-study. Five serial blood samples were collected on a single visit between 4 and 8 weeks after initiation of antituberculosis treatment. Concentration-time data for isoniazid and acetyl-isoniazid were analysed using non-linear mixed-effects models. RESULTS: Isoniazid concentrations from 150 patients were available for analysis, and 79 of these (53%) also had concentrations of acetyl-isoniazid. Isoniazid pharmacokinetics was best described with a two-compartment disposition model with lagged first-order absorption and elimination using a semi-mechanistic model describing hepatic extraction. The model identified two elimination pathways, separating formation of acetyl-isoniazid from other routes of metabolism. The predicted AUC0-24 is reduced by 29% in patients who are fast acetylators of isoniazid and receiving efavirenz-based ART (6.73 versus 4.68 mg·h/L). In slow acetylators, efavirenz-based ART had no effect on isoniazid exposure (AUC0-24 = 17.5 mg·h/L). CONCLUSIONS: Efavirenz-based ART affects the acetylation metabolic pathway amongst rapid acetylators, resulting in reduced exposure to isoniazid. Pharmacokinetics of isoniazid and acetyl-isoniazid were not influenced by the 50% increase in rifampicin dose.
引用
- Chirehwa MT, McIlleron H, Wiesner L, et al. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. J Antimicrob Chemother. 2019. PMID: 30239829. doi:10.1093/jac/dky378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。